BRE-13: Mediterranean Diet (BRE-13)
BRE-13: Mediterranean Diet-A Presurgical Window of Opportunity Trial Among Women With Breast Cancer
Explore the effect of MedDiet vs. Usual Diet on circulating and breast tumor fatty acid profiles. The investigators aim to examine impact on tumor biology in newly diagnosed participants.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
- Kosttilskud: Explore the effect of MedDiet vs. Usual Diet on Fatty Acid Profile
- Diagnostisk test: Explore the effect of MedDiet vs. Usual Diet on Breast Tumor Tissue
- Diagnostisk test: Explore the effect of MedDiet vs. Usual Diet on Lipids
- Diagnostisk test: Explore the effect of MedDiet vs. Usual Diet on tumor tissue expression
Detaljeret beskrivelse
Conduct a 3-week presurgical window trial among 30 women with stage I-III luminal breast cancer. Participants will be randomized 1:1 to a controlled MedDiet or an enhanced usual-care control. This study will generate critical translational data on how dietary fat composition influences tumor metabolism and immune response, informing future diet-based cancer interventions.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Lisa Marie Tussing-Humphreys, Ph.D.
- Telefonnummer: 312 355 5521
- E-mail: tussing@uic.edu
Undersøgelse Kontakt Backup
- Navn: Meredith Russell
- Telefonnummer: 312 355 5112
- E-mail: mrussel3@uic.edu
Studiesteder
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- Rekruttering
- University of Illinois at Chicago Campus
-
Kontakt:
- Meredith Russell, BS
- Telefonnummer: 312 355 5112
- E-mail: mrussel3@uic.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years;
- Newly diagnosed stage I-III luminal breast cancer
- Planned surgical resection at UI Health
- Ability to speak, read, write, and understand English
- A Mediterranean Eating Pattern for Americans (MEPA-III) score <13 indicating that they do not currently follow a MedDiet;
- ECOG performance status of 0 or 1.
Exclusion Criteria:
- Currently following a MedDiet, vegan diet, or dietary restrictions (e.g., religious, food intolerance/allergy) that preclude adoption of a MedDiet;
- Lack of access to a space to safely store and reheat foods items;
- Living in facility that provides meals;
- Chronic CKD stage 3+ or currently receiving dialysis treatment;
- History of GI surgery involving removal of part of the stomach or intestines;
- Type 1 or Type 2 diabetes;
- Autoimmune or Inflammatory disease or immunocompromised; and
- Cachexia.
We will not exclude other neoadjuvant treatments. Adults unable to consent Individuals who are not yet adults (infants, children, teenagers) Pregnant or breastfeeding women Prisoners
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: Med Diet
Mediterranean Diet (MedDiet) is a dietary pattern characterized by a low intake of saturated fats and a high intake of unsaturated fats, with olive oil as the primary culinary fat (7, 8). |
Fatty acid profile (chain length and degree of saturation) in circulation of blood, tumor tissue, and tumor interstitial fluid. Fatty acid profile (chain length and degree of saturation) in breast tumor tissue. Lipid availability in blood, tumor tissue, and tumor interstitial fluid. Tumor tissue will explore the effect of MedDiet vs. Usual Diet on tumor proliferation (Ki67) and expression of NK and CD8 T cells and chylomicrons (Apo48 staining). |
|
Ingen indgriben: Usual Diet
Dietary fat and cancer has been conducted in preclinical models of diet-induced obesity, where high-fat diets promote tumor growth |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Aim 1a
Tidsramme: 3 weeks
|
Fatty acid profile (chain length and degree of saturation) in blood. |
3 weeks
|
|
Aim 1b
Tidsramme: 3 weeks
|
Lipid availability in blood, tumor tissue, and interstitial fluid. |
3 weeks
|
|
Aim 1c
Tidsramme: 3 weeks
|
Fatty acid profile (chain length and degree of saturation) in breast tumor tissue, |
3 weeks
|
|
Aim 2a
Tidsramme: 3 weeks
|
peripheral blood monocyte cells from the electronic health record. |
3 weeks
|
|
Aim 2b
Tidsramme: 3 weeks
|
Tumor tissue will explore the effects on tumor proliferation (Ki67) cells. |
3 weeks
|
|
Aim 2c
Tidsramme: 3 weeks
|
Tumor tissue will explore the effects on expression of NK cells. |
3 weeks
|
|
Aim 2d
Tidsramme: 3 weeks
|
Tumor tissue will explore the effects on CD8 T cells(immunohistochemistry) cells. |
3 weeks
|
|
Aim 2e
Tidsramme: 3 weeks
|
Tumor tissue will explore the effects on chylomicrons (Apo48 staining) cells. |
3 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Exploratory aim a
Tidsramme: 3weeks
|
Stool will be used to analyze gut microbiome changes using shotgun bioinformatics and downstream bioinformatics to study compositional and metabolic changes among the two study arms. |
3weeks
|
|
Exploratory aim b
Tidsramme: 3weeks
|
Stool will be used to analyze downstream bioinformatics to study compositional and metabolic changes among the two study arms. |
3weeks
|
|
Exploratory aim c
Tidsramme: 3weeks
|
Stool will be used to analyze metabolic changes among the two study arms. |
3weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Lisa Marie Tussing-Humphreys, Ph.D, University of Illinois Chicago Campus
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 2026-0573
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .